tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate | 1187451-32-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate
• 英文别名: Tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate；tert-butyl 2-[[6-(aminomethyl)pyridin-2-yl]-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetate
• CAS: 1187451-32-6
• 化学式: C₁₇H₂₇N₃O₄
• 分子量: 337.419
• InChiKey: VGCVWYXUEQRQFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate 在 三丁基膦 、 偶氮二甲酰胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 tert-butyl (tert-butoxycarbonyl(6-((4-(pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-yl)amino)acetate
  参考文献：
  名称：

  EP2476678

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl [tert-butoxycarbonyl(6-hydroxyiminomethylpyridin-2-yl)amino]acetate 在 钯 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以to obtain 2.48 g of the title compound as colorless oily product的产率得到tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate
  参考文献：
  名称：

  AMINOPYRIDINE COMPOUND

  摘要：

  本发明涉及一种由式(I)表示的化合物或其药学上可接受的盐，以及含有该化合物的医药组合物，以及用于治疗或预防呼吸系统疾病或青光眼的医药组合物。

  公开号：

  US20120259123A1

文献信息

• 치환 비아릴 화합물
  申请人：UBE Corporation 유비이 가부시키가이샤(519980963229)

  公开号：KR20150135460A

  公开（公告）日：2015-12-02

  본 발명은 화학식 (I) (화학식 중, R, W, R 및 Z는 특허청구범위 및 명세서에서 정의한 바와 같음)로 표현되는 치환 비아릴 화합물 또는 그의 약리상 허용되는 염을 제공한다. 본 발명의 화합물은 우수한 폐섬유 아세포 증식 억제 작용을 갖는 점에서, 간질성 폐렴·폐섬유증에 대한 치료약 및/또는 예방약으로서 유용하다.

  This invention provides a substituted biaryl compound or a pharmaceutically acceptable salt thereof represented by the chemical formula (I) (wherein, R, W, R, and Z are as defined in the claims and specification) . The compounds of the present invention are useful as therapeutic agents and/or prophylactic agents for idiopathic pulmonary fibrosis and pulmonary fibrosis due to their excellent pulmonary fibroblast proliferation inhibitory activity.
• ANILINE COMPOUND
  申请人：Iwamura Ryo

  公开号：US20120184747A1

  公开（公告）日：2012-07-19

  This is to provide a novel aniline compound represented by the following formula (I) having an excellent broncho dilatory action based on potent EP2 agonistic action. A compound represented by the formula (I): or a salt thereof.

  这是提供一种新的苯胺化合物，其化学式如下（I），基于强效EP2激动作用具有出色的支气管扩张作用。 化合物的化学式（I）： 或其盐。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE
  申请人：UBE INDUSTRIES, LTD.

  公开号：US20160213657A1

  公开（公告）日：2016-07-28

  Provided is a pharmaceutical composition containing, as an active ingredient thereof, a substituted biaryl compound represented by general formula (I), wherein, R 1 , W, R 2 and Z are as defined in the claims and description, or a pharmacologically acceptable salt thereof. The pharmaceutical composition of the present invention is useful as a therapeutic drug and/or prophylactic drug for chronic obstructive pulmonary disease due to having an excellent anti-inflammatory effect.

  提供的是一种药物组合物，其活性成分是由一般式(I)表示的取代联苯化合物，其中R1、W、R2和Z如权利要求和描述中所定义，或其药理学上可接受的盐。本发明的药物组合物由于具有出色的抗炎效果，可用作治疗慢性阻塞性肺病的治疗药物和/或预防药物。
• AMINOPYRIDINE COMPOUND
  申请人：Iwamura Ryo

  公开号：US20120259123A1

  公开（公告）日：2012-10-11

  The present invention relates to a compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, a medical composition containing the same, and a medical composition for the treatment or prophylaxis of respiratory diseases or glaucoma.

  本发明涉及一种由以下公式（I）表示的化合物或其药学上可接受的盐，含有该化合物的医药组合物，以及用于治疗或预防呼吸道疾病或青光眼的医药组合物。
• MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA
  申请人：Hagihara Masahiko

  公开号：US20120190852A1

  公开（公告）日：2012-07-26

  The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R 1 , R 2 and R 3 each independently represent a hydrogen atom or C 1 -C 6 alkyl group, Y represents a bicyclic heteroaromatic ring group which may be substituted by a group(s) selected from the group consisting of a halogen atom, C 1 -C 6 alkyl group, halogeno C 1 -C 6 alkyl group, C 1 -C 6 alkoxyl group, halogeno C 1 -C 6 alkoxyl group and C 1 -C 6 alkylthio group or a group -Q 1 -Q 2 wherein Q 1 represents an arylene group or 5- to 6-membered heteroarylene group, Q 2 represents an aromatic group or a 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C 1 -C 6 alkyl group, halogeno C 1 -C 6 alkyl group, C 1 -C 6 alkoxyl group and halogeno C 1 -C 6 alkoxyl group, Z represents an aromatic group or a 5- to 6-membered heteroaromatic ring group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C 1 -C 6 alkyl group, halogeno C 1 -C 6 alkyl group, C 1 -C 6 alkoxyl group and halogeno C 1 -C 6 alkoxyl group, or a pharmaceutically acceptable salt thereof as an effective ingredient.

  本发明提供了一种治疗或预防青光眼的医药组合物，其包含由公式（1）表示的吡啶基氨基乙酸化合物：其中R1，R2和R3各自独立地表示氢原子或C1-C6烷基，Y表示一个双环杂芳基环团，可以被选自卤素原子、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基和C1-C6烷基硫基或-Q1-Q2基团取代，其中Q1表示芳烃基或5-至6-成员杂芳基基团，Q2表示芳香基或5-至6-成员环杂环基团，可以被选自卤素原子、羟基、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基和卤代C1-C6烷氧基等基团取代，Z表示芳香基或5-至6-成员杂芳基环团，可以被选自卤素原子、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基和卤代C1-C6烷氧基等基团取代，或其药学上可接受的盐作为有效成分。